PD-1/PD-L1
PD-1/PD-L1 inhibitors are immune checkpoint inhibitors that block the interaction between the programmed cell death protein 1 (PD-1) on T cells and its ligand PD-L1 on cancer cells. This interaction normally suppresses the immune response and allows cancer cells to evade immune detection. By inhibiting PD-1/PD-L1, these inhibitors enhance the immune system's ability to recognize and destroy cancer cells, inducing apoptosis and tumor regression. PD-1/PD-L1 inhibitors are critical in immunotherapy research and cancer treatment. At CymitQuimica, we offer a range of high-quality PD-1/PD-L1 inhibitors to support your research in immuno-oncology, apoptosis, and cancer therapy.
Found 147 products for "PD-1/PD-L1".
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Pembrolizumab
CAS:Pembrolizumab (MK-3475) is a humanized monoclonal antibody.Cost-effective and quality-assured.Purity:95% - 99.70%Color and Shape:Transparent LiquidMolecular weight:149 kDaNivolumab
CAS:Nivolumab is a monoclonal antibody, a humanized IgG4 antibody to PD-1. Nivolumab has antitumor activity. Cost-effective and quality-assured.Purity:98% - 98%Color and Shape:LiquidMolecular weight:143.62 kDaBMS-1001
CAS:BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay).Formula:C35H34N2O7Purity:98.43%Color and Shape:SolidMolecular weight:594.7Ref: TM-T8470
1mg58.00€5mg124.00€1mL*10mM (DMSO)172.00€10mg177.00€25mg299.00€50mg424.00€100mg587.00€200mg792.00€BMS-8
CAS:BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.Formula:C27H28BrNO3Purity:98.88%Color and Shape:SolidMolecular weight:494.42Ref: TM-T26859
1mg37.00€5mg79.00€1mL*10mM (DMSO)86.00€10mg124.00€25mg222.00€50mg340.00€100mg505.00€200mg705.00€ARB-272572
CAS:ARB-272572 is a PD-L1 signaling inhibitor that produces immunostimulatory activity in human primary cells.Formula:C32H36N6O4Purity:97.36% - 98.07%Color and Shape:White SolidMolecular weight:568.67Ref: TM-T39914
1mg123.00€5mg295.00€1mL*10mM (DMSO)353.00€10mg425.00€25mg712.00€50mg1,035.00€100mg1,485.00€200mg1,998.00€Envafolimab
CAS:Envafolimab (ASC 22) is a humanized antibody targeting PD-L1, with anticancer activity, blocking the PD-L1 and PD-1 interaction.Purity:95%Color and Shape:Transparent LiquidMolecular weight:80 kDaSocazolimab
CAS:Socazolimab (ZKAB001) is a monoclonal antibody targeting PD-L1 with antitumor activity, used in studies of recurrent or metastatic cervical cancer.Purity:95%Color and Shape:LiquidMolecular weight:143.06 kDaBMS-1166-n-piperidine-co-n-piperazine dihydrochloride
CAS:BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride is a resorcinol di-Ph ether scaffold-based programmed cell death-1 (PD-1)/programmed cell death ligand 1 (Formula:C41H45Cl3N4O5Purity:98.94%Color and Shape:SoildMolecular weight:780.18Peresolimab
CAS:Peresolimab is a humanized antibody targeting PD-1, potentially stimulating immune inhibitory pathways for autoimmune disease research.Purity:95% - 97.8% (SDS-PAGE); 99.3% (SEC-HPLC)Color and Shape:LiquidMolecular weight:145.14 kDaGilvetmab
CAS:Gilvetmab is a caninized anti-PD-1 antibody approved for veterinary use, researched for stage I-III mast cell tumors and stage II-III melanoma in dogs.Purity:95% - 97.9% (SDS-PAGE); 97.4% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:147.95 kDaAcasunlimab
CAS:Acasunlimab (GEN1046) is a bsAb that targets PD-L1 and 4-1BB, boosting T/NK cells and blocking PD-1/PD-L1 in cancer research.Color and Shape:LiquidVudalimab
CAS:Vudalimab is a bispecific antibody inhibiting PD-1 and CTLA-4 for tumor-targeted T cell activation.Purity:98.93%Color and Shape:Transparent LiquidToripalimab
CAS:Toripalimab is a humanized anti-PD-1 monoclonal antibody used as an immune checkpoint inhibitor in research for advanced malignancies like nasopharyngeal carcinoma.Purity:95% - 95.2% (SDS-PAGE); 96.8% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:147.29 kDaAnti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12)
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) detects phosphorylated PD-1 by WB and flow cytometry.Purity:95% - 97.3% (SDS-PAGE); 96.9% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:146.24 kDaAnti-Mouse PD-1 Antibody (S-5001)
Anti-MousePD-1Antibody (S-5001) is an IgG1 antibody inhibitor that targets mouse PD-1.Color and Shape:Odour LiquidReozalimab
CAS:Reozalimab (LY3434172) is a bispecific monoclonal antibody targeting PD-1/PD-L1, antitumour and enhances T-cell activation in vitro.Purity:95% - 98.1% (SDS-PAGE); 96.2% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:144.16 kDaVisugromab
CAS:Visugromab (CTL-002) is a monoclonal antibody that targets and neutralises GDF-15.Purity:95% - 98.8% (SDS-PAGE); 97.5% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:144.50 kDaLesabelimab
CAS:Lesabelimab (LDP) is an anti-CD274 monoclonal antibody of the immunoglobulin G1-kappa subclass.Purity:97.8% (SDS-PAGE); 95.1% (SEC-HPLC) - 97.8% (SDS-PAGE); 95.1% (SEC-HPLC)Color and Shape:LiquidIvonescimab
CAS:Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody with cancer immunotherapy and anti-angiogenic effects, NSCLC).Purity:95% - >95.0% (SDS-PAGE); 98.99% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:201.12 kDaGeptanolimab
CAS:Geptanolimab (CBT-501) is a humanized IgG4κ antibody against PD-1, blocking PD-L1/PD-L2 binding to reactivate T cell activity.Purity:95% - 99.5% (SDS-PAGE); 97.6% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:144.14 kDaCosibelimab
CAS:Cosibelimab, a fully human monoclonal antibody, blocks PD-L1, enabling ADCC and CDC against cancer cells.Color and Shape:LiquidTagitanlimab
CAS:Tagitanlimab, Humanized anti-PD-L1 mAb, blocks PD-L1-PD-1 interaction, for nasopharyngeal carcinoma (NPC) research.Purity:95% - 95%Color and Shape:Transparent LiquidPucotenlimab
CAS:Pucotenlimab (HX008) is an anti-PD-1 mAb that blocks PD-1/PD-L1/2 interactions, restoring immune function against solid tumours.Purity:95%Color and Shape:LiquidMolecular weight:144.77 kDaSugemalimab
CAS:Sugemalimab, Anti-PD-L1 mAb, induces ADCC, for EGFR/ALK-negative metastatic NSCLC, solid tumors, and lymphoma research.Purity:95% - 95%Color and Shape:Transparent LiquidRulonilimab
CAS:Rulonilimab is a fully human mAb targeting PD-1 that restores T-cell anti-tumor activity by blocking the PD-1/PD-L1 pathway, commonly used in combination therapy research for HCC.Color and Shape:LiquidRosnilimab
CAS:Rosnilimab is a PD-1 agonist that inhibits T cell proliferation and depletes T cells, enabling research into inflammatory diseases.Purity:95% - 98.9% (SDS-PAGE); 98.7% (SEC-HPLC)Color and Shape:LiquidMolecular weight:146.57 kDaAnti-Human PD-1/CD279 Antibody (J116)
Anti-Human PD-1/CD279 Antibody (J116) is a PD-1 monoclonal antibody for cancer immunotherapy research.Purity:95% - 97.9% (SDS-PAGE); 95.1% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:145.88 kDaAnti-Mouse PD-1/CD279 (D265A) Antibody (29F.1A12)
Anti-Mouse PD-1/CD279 (D265A) Antibody (29F.1A12) blocks PD-1 ligands, used in cancer and immunology research.Purity:95% - 97.9% (SDS-PAGE); 99.3% (SEC-HPLC)Molecular weight:145.5 kDaBMS-37
CAS:BMS-37 is a novel inhibitor of PD-1/PD-L1 immune checkpoint.Formula:C27H32N2O4Color and Shape:SolidMolecular weight:448.55PD-1/PD-L1-IN-20
CAS:PD-1/PD-L1-IN-20 is a small molecule inhibitor of PD-1/PD-L1 protein-protein interaction.Formula:C30H26BrClN2O3Color and Shape:SolidMolecular weight:577.9PD-1-IN-22
CAS:PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor(IC50 of 92.3 nM).Formula:C25H25N5O4Purity:99.51%Color and Shape:SolidMolecular weight:459.5PD-1/PD-L1-IN-NP19
CAS:PD-1/PD-L1-IN-NP19: a PD-1/PD-L1 inhibitor with 12.5 nM IC50, may boost antitumor immunity.Formula:C33H31ClN2O4Purity:96.70%Color and Shape:White SolidMolecular weight:555.06PD-1/PD-L1-IN-34
CAS:PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) effectively inhibits the PD-1/PD-L1 interaction (IC 50 = 0.029 μM) and demonstrates selective binding affinity to PD-L1Formula:C35H33ClN2O3Purity:98%Color and Shape:SolidMolecular weight:565.1PD-L1-IN-2
CAS:PD-L1-IN-2, a Naamidine J derivative, serves as a promising antineoplastic immunomodulator by hindering PD-L1 activity.Formula:C33H38N4O6Purity:98%Color and Shape:SolidMolecular weight:586.68ASC-69
CAS:ASC-69 (APY69) is a promising potent inhibitor of the PD-1/PD-L1 signaling pathway, classified as a small-molecule compound [1].Formula:C19H19N7Purity:99.66%Color and Shape:White SolidMolecular weight:345.4PD-1/PD-L1-IN-27
CAS:PD-1/PD-L1-IN-27: potent anti-cancer, IC50 134nM, minimal T cell harm, boosts CD8+ T cells, reduces fatigue.Formula:C44H35NO6Purity:98%Color and Shape:SolidMolecular weight:673.75PD-1/PD-L1-IN-33
CAS:PD-1/PD-L1-IN-33 (Compound N11), a PD-1/PD-L1 inhibitor, effectively impedes the interaction between PD-1 and PD-L1 with an IC50 of 6.3 nM.Formula:C26H27N5OPurity:98%Color and Shape:SolidMolecular weight:425.53PD-1/PD-L1-IN-26
CAS:PD-1/PD-L1-IN-26 is a strong inhibitor with IC50 of 0.0380 μM that may boost immune response in cancer by aiding CD4+ T cell entry to tumors.Formula:C43H52N4O8Purity:98%Color and Shape:SolidMolecular weight:752.89PD-L1-IN-3
CAS:PD-L1-IN-3 is a PD-1/PD-L1 inhibitor for the study of tumors and immune diseases.Formula:C19H15ClFN2OSPurity:99.47%Color and Shape:SolidMolecular weight:373.85PD-L1/VISTA-IN-1
CAS:PD-L1/VISTA-IN-1 (Compound P17) is an orally active dual inhibitor targeting PD-L1 and VISTA. It effectively hinders the PD-1/PD-L1 interaction (IC50: 0.1492 μM) and the VISTA pathway (KD: 0.2723 μM), leading to the reactivation of T cells. Additionally, PD-L1/VISTA-IN-1 exhibits antitumor activity.Formula:C22H24N4O4Color and Shape:SolidMolecular weight:408.45LLW-018
CAS:LLW-018 is a potent PD-1/PD-L1 inhibitor with an IC50 value of 2.61 nM. It can disrupt the PD-1/PD-L1 interaction, with a cell-based PD-1/PD-L1 blocking bioassay IC50 value of 0.88 μM. LLW-018 holds potential for research in immune-related diseases.Formula:C35H38Cl2N4O5SColor and Shape:SolidMolecular weight:697.67PD-1/PD-L1-IN-55
CAS:PD-1/PD-L1-IN-55 (compound D6) is a potent PD-1/PD-L1 inhibitor with an IC50 of 4.8 nM. It enhances IFN-γ secretion and decreases the proportion of late apoptosis due to PD-L1.Formula:C25H23ClN2O3Color and Shape:SolidMolecular weight:434.92Enpp-1-IN-25
CAS:Enpp-1-IN-25 (Compound 30) is an ENPP1 inhibitor with an IC50 of 8.05 nM and exhibits low oral bioavailability. By inhibiting cGAMP degradation, it effectively activates the intracellular STING pathway. Enpp-1-IN-25 can enhance immune cell infiltration and type I interferon response in the tumor microenvironment, thereby increasing the antitumor efficacy of anti-PD-L1 antibodies. It is applicable for research in cancer immunotherapy.Formula:C15H21N5O4SColor and Shape:SolidMolecular weight:367.423PD-1-IN-17
CAS:PD-1-IN-17 is an inhibitor of programmed cell death-1 (PD-1). PD-1-IN-17 inhibits 92% splenocyte proliferation at 100 nM.Formula:C13H22N6O7Purity:99.6%Color and Shape:SolidMolecular weight:374.35PD-1/PD-L1-IN-53
CAS:PD-1/PD-L1-IN-53 (compound B3) serves as an inhibitor targeting both the PD-1/PD-L1 and VISTA signaling pathways. It is utilized in cancer research.Formula:C31H37N3O4Color and Shape:SolidMolecular weight:515.64PD-L1-IN-7
CAS:PD-L1-IN-7 (compound CB31) serves as a PD-L1 inhibitor, effectuating PD-L1 internalization and retention within cells. It restrains the PD-1/PD-L1 interaction (IC 50: 0.2 nM), alters glycosylation patterns, and facilitates PD-L1 degradation. Additionally, PD-L1-IN-7 enhances T cell infiltration, boosts T cell function, and augments the capacity to destroy tumor cells.Formula:C46H50N6O7Color and Shape:SolidMolecular weight:798.93INCB086550
CAS:INCB086550 (PD-1/PD-L1-IN-8) (example 24) is a PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM.Formula:C41H39N7O4Purity:98.49%Color and Shape:SolidMolecular weight:693.79
